公开(公告)号：EP3958867A1

公开(公告)日：2022-03-02

申请号：EP20794764.9

申请日：2020-03-11

申请人： CONVERGENE LLC ,  The Government of the United States of America as represented by the Secretary, Department of Health and Human Services

发明人： YOSHIOKA, Makoto ,  YANG, Shyh-Ming ,  STROVEL, Jeffrey ,  MALONEY, David ,  JADHAV, Ajit ,  URBAN, Daniel Jason

IPC分类号： A61K31/517 ,  C07D239/94 ,  A61P35/00

公开(公告)号：EP3851110A1

公开(公告)日：2021-07-21

申请号：EP20204879.9

申请日：2016-05-27

申请人： Kite Pharma, Inc. ,  The Government of the United States of America as represented by the Secretary, Department of Health and Human Services

发明人： BOT, Adrian ,  GO, William ,  JAIN, Rajul ,  WIEZOREK, Jeffrey S. ,  KOCHENDERFER, James N. ,  ROSENBERG, Steven A.

IPC分类号： A61K31/7076 ,  A61K31/675 ,  A61P35/02

摘要： The invention provides methods of increasing the efficacy of a T cell therapy in a patient in need thereof. The invention includes a method of conditioning a patient prior to a T cell therapy, wherein the conditioning involves administering a combination of cyclophosphamide and fludarabine.

公开(公告)号：EP3799874A1

公开(公告)日：2021-04-07

申请号：EP20197500.0

申请日：2008-05-30

申请人： The Government of The United States of America, as represented by The Secretary, Department of Health and Human Services

发明人： HUIZING, Marjan ,  GAHL, William. ,  MANOLI, Irini. ,  KLOOTWIJK, Enriko.

IPC分类号： A61K31/7008 ,  A61P13/12 ,  A61P21/00 ,  A61P3/10

摘要： The invention relates to compositions and methods for treating kidney and muscle dysfunction that involves use of therapeutic amounts of N -acetyl mannosamine.

公开(公告)号：EP3269728A3

公开(公告)日：2018-02-28

申请号：EP17181475.9

申请日：2012-10-18

申请人： The Government of The United States of America as represented by The Secretary, Department of Health and Human Services

发明人： CHANG, Gwong-jen, J. ,  CRILL, Wayne, D. ,  HUGHES, Holly R. ,  DAVIS, Brent, S.

IPC分类号： C07K14/18 ,  C12N15/40 ,  A61K39/12 ,  A61K39/295

CPC分类号： A61K39/12 ,  A61K2039/5258 ,  A61K2039/53 ,  A61K2039/57 ,  A61K2039/575 ,  A61K2039/6031 ,  A61K2039/6075 ,  A61K2039/70 ,  C07K14/005 ,  C12N7/00 ,  C12N2770/24122 ,  C12N2770/24123 ,  C12N2770/24134 ,  C12N2770/24151 ,  C12N2770/24171 ,  Y02A50/386

摘要： Described herein are dengue virus E-glycoprotein polypeptides containing mutations that eliminate immunodominant cross-reactive epitopes associated with immune enhancement.
The disclosed dengue virus E-glycoproteins optionally further include mutations that introduce a strong CD4 T cell epitope. The disclosed E-glycoprotein polypeptides, or nucleic acid molecules encoding the polypeptides, can be used, for example, in monovalent or tetravalent vaccines against dengue virus. The dengue virus E-glycoprotein polypeptides have amino acid substitutions at residues corresponding to position 106, 107, 310 and 311, and either position 364 or position 389 of dengue serotype 1 (DENV-1) E-glycoprotein. The provided E-glycoprotein polypeptides optionally further include mutations corresponding to positions 468, 478, 482 and 487 of DENV-1 E-glycoprotein.

公开(公告)号：EP3205352A1

公开(公告)日：2017-08-16

申请号：EP17155603.8

申请日：2003-04-25

申请人： The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services

发明人： Whitehead, Stephen S. ,  Murphy, Brian R. ,  Markoff, Lewis ,  Falgout, Barry ,  Blaney, Joseph ,  Hanley, Kathryn ,  Lai, Ching-Juh

IPC分类号： A61K39/00 ,  A61K39/12 ,  A61K39/42 ,  C12N7/00 ,  C07H21/04

CPC分类号： C12N7/00 ,  A61K39/12 ,  A61K2039/5254 ,  A61K2039/5256 ,  A61K2039/70 ,  C12N2770/24134 ,  C12N2770/24161 ,  Y02A50/386

摘要： The invention relates to a dengue virus tetravalent vaccine containing a common 30 nucleotide deletion (Δ30) in the 3'-untranslated region of the genome of dengue virus serotypes 1, 2, 3, and 4, or antigenic chimeric dengue viruses of serotypes 1, 2, 3, and 4.

摘要翻译： 本发明涉及登革病毒四价疫苗，其在登革病毒血清型1,2,3和4的基因组的3'非翻译区或血清型1，2，3和4的抗原嵌合登革病毒中含有共同的30个核苷酸缺失（Δ30） 2,3和4。

公开(公告)号：EP3006041A1

公开(公告)日：2016-04-13

申请号：EP15195219.9

申请日：2007-03-16

申请人： The Government of the United States of America, as represented by The Secretary, Department of Health and Human Services

发明人： LEE, Che-Hung Robert

IPC分类号： A61K39/385 ,  A61K39/08 ,  A61K39/095 ,  A61K39/00 ,  A61K47/48

CPC分类号： C07K1/084 ,  A61K39/116 ,  A61K39/385 ,  A61K47/6415 ,  A61K47/646 ,  A61K2039/6037 ,  A61K2039/62 ,  Y02A50/484

摘要： Methods for preparing complex multivalent immunogenic conjugates that include simultaneously reacting a plurality or immunogenic-distinct polysaccharides with at least one protein to make the complex multivalent immunogenic conjugates. The simultaneous reaction involves reaction of a hydrazide group on one reactant with an aldehyde or cyanate ester group on the other reactant.

摘要翻译： 制备复合多价免疫原性缀合物的方法，其包括同时使多种或免疫原性不同的多糖与至少一种蛋白质反应以制备复合多价免疫原性缀合物。 同时反应包括一个反应物上的酰肼基团与另一反应物上的醛或氰酸酯基团的反应。

公开(公告)号：EP3002008A1

公开(公告)日：2016-04-06

申请号：EP15188438.4

申请日：2011-03-11

申请人： New York University ,  The Government of The United States of America, as represented by The Secretary, Department of Health and Human Services

发明人： Littman, Dan ,  Huh, Jun, R. ,  Huang, Wenwei ,  Huang, Ruili ,  Englund, Erika, Elaine

IPC分类号： A61K31/12 ,  A61K31/33 ,  A61K31/4453 ,  A61K31/4525 ,  A61K31/535 ,  C07D317/54 ,  C07D317/60 ,  C07D401/10 ,  C07D403/14 ,  C07D405/06 ,  C07C235/34 ,  C07C235/36

CPC分类号： A61K31/55 ,  A61K31/12 ,  A61K31/33 ,  A61K31/4025 ,  A61K31/404 ,  A61K31/4453 ,  A61K31/451 ,  A61K31/4525 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/535 ,  A61K31/5377 ,  C07C235/34 ,  C07C235/36 ,  C07D211/06 ,  C07D211/16 ,  C07D307/52 ,  C07D307/81 ,  C07D317/54 ,  C07D317/60 ,  C07D401/10 ,  C07D403/14 ,  C07D405/06 ,  C07D413/06 ,  C07D413/14

摘要： Amido compounds are disclosed that have a formula represented by the following:

and wherein n1, n2, R 1a , R 1b , R 2 , R 3 , R 4 , R 5 , and R 6 are as described herein. The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammatory conditions, autoimmune disorders, cancer, and graft-versus-host disease.

摘要翻译： 公开了具有由以下表示的式的酰氨基化合物：其中n1，n2，R 1a，R 1b，R 2，R 3，R 4，R 5和R 6如本文所述。 这些化合物可以制备成药物组合物，并且可以用于预防和治疗包括人在内的哺乳动物中的各种病症，包括作为非限制性实例，炎性病症，自身免疫疾病，癌症和移植物抗 - 宿主病。

公开(公告)号：EP2994754A1

公开(公告)日：2016-03-16

申请号：EP14729563.8

申请日：2014-05-12

申请人： The Government of The United States of America as represented by The Secretary, Department of Health and Human Services

发明人： KHUDYAKOV, Yury, E. ,  OBRIADINA, Anna

IPC分类号： G01N33/50

CPC分类号： G01N33/5767 ,  C07K14/005 ,  C12N7/00 ,  C12N2770/24222 ,  C12N2770/24231 ,  G01N2333/186 ,  G01N2469/20

摘要： Compositions and processes are provided for the robust detection of hepatitis C virus in a sample. Compositions include amino acid sequences of HCV core region including or exclusive to residues 14-31 or 50-90 of the HCV core protein. Also provided are processes of detecting HCV in a sample whereby the provided peptides are optionally used alone or in conjunction with antibodies that do not recognize the peptides so that detection is independent of seroconversion in a subject. Using the compositions and processes, HCV can be detected in a sample prior to or following seroconversion leading to robust HCV detection and diagnosis.

摘要翻译： 提供了组合物和方法，用于在样品中强力检测丙型肝炎病毒。 组合物包括HCV核心区域的氨基酸序列，包括或排除HCV核心蛋白质残基14-31或50-90的氨基酸序列。 还提供了在样品中检测HCV的方法，其中所提供的肽任选地单独使用或与不识别肽的抗体结合，使得检测不依赖于受试者的血清转化。 使用组合物和方法，可以在血清转化之前或之后在样品中检测HCV，从而导致强烈的HCV检测和诊断。

公开(公告)号：EP2292630B1

公开(公告)日：2015-11-25

申请号：EP10010885.1

申请日：1997-09-26

申请人： The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services

发明人： Saavedra, Joseph E. ,  Keefer, Larry K.

IPC分类号： C07H19/06 ,  C07H19/16 ,  A61K31/7064 ,  A61P9/00 ,  A61P11/00 ,  A61P15/10 ,  A61P29/00 ,  A61P31/00

CPC分类号： C07D213/64 ,  C07C291/08 ,  C07D207/16 ,  C07D239/34 ,  C07D295/30 ,  C07H19/06 ,  C07H19/16

公开(公告)号：EP2707388A2

公开(公告)日：2014-03-19

申请号：EP12782672.5

申请日：2012-03-23

申请人： Duke University ,  The Government of The United States of America, as represented by The Secretary, Department of Health and Human Services

发明人： MASCOLA, John, R. ,  NABEL, Gary ,  HAYNES, Barton, F. ,  WU, Xueling ,  KEPLER, Thomas, B. ,  KWONG, Peter

IPC分类号： C07K16/10 ,  C12N15/13 ,  A61K39/42 ,  A61P31/18

CPC分类号： C07K16/1063 ,  A61K39/42 ,  C07K2317/21 ,  C07K2317/565 ,  C07K2317/76 ,  G01N33/56988

摘要： Antibody VRC01 represents a human immunoglobulin that neutralizes—˜90% of diverse HIV-1 isolates. To understand how such broadly neutralizing HIV-1 antibodies develop and recognize the viral envelope, we used X-ray crystallography and 454 pyrosequencing to characterize additional antibodies from HIV-1-infected individuals. Crystal structures revealed a convergent mode of binding of different antibodies to the same CD4-binding-site epitope. Antibody recognition was achieved through the evolution of complementary contact domains that were generated in diverse ways. Phylogenetic analysis of expressed heavy and light chains determined by deep sequencing revealed a common pathway of antibody heavy chain maturation confined to IGHV1-2*02 lineage that could pair with different light chains. The maturation pathway inferred by antibodyomics reveals that diverse antibodies evolve to a highly affinity-matured state to recognize an invariant viral structure, providing insight into the development and evolution of broadly neutralizing HIV-1 immunity.